LH/hCG action and development of ovarian cancer--a short review on biological and clinical/epidemiological aspects.
A link between infertility therapy, especially ovulation induction therapy using gonadotropins, and the development of ovarian cancer has long been an issue of debate since an epidemiological report supporting the possibility appeared in 1992. A number of clinical/epidemiological and biological studies, including a few that we conducted, have revealed various facts regarding this issue. The aim of this short review was to summarize the last 10 years findings and to address the implications of the debates on this issue.
Mandai
Masaki
M
Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan. mandai@kuhp.kyoto-u.ac.jp
Konishi
Ikuo
I
Kuroda
Hideki
H
Fujii
Shingo
S
D017209:Apoptosis / Q000187:drug effects; D002277:Carcinoma / Q000453:epidemiology* / Q000209:etiology* / Q000378:metabolism; D006063:Chorionic Gonadotropin / Q000502:physiology* / Q000627:therapeutic use; D005260:Female; D005300:Fertility Agents, Female / Q000009:adverse effects; D006801:Humans; D007986:Luteinizing Hormone / Q000502:physiology* / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000453:epidemiology* / Q000209:etiology* / Q000378:metabolism; D010053:Ovary / Q000166:cytology / Q000187:drug effects; D011974:Receptors, LH / Q000378:metabolism
D006063:Chorionic Gonadotropin; D005300:Fertility Agents, Female; D011974:Receptors, LH; D007986:Luteinizing Hormone